Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLS-101 in Hematological Malignancies (waveLINE-001)
NCT03833180Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zilovertamab vedotin in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 9 more (3 arms), sponsored by Merck & Co. Primary endpoints: Maximum Tolerated Dose and Recommended Dosing Regimen. Started Mar 2019; status: completed.
02
Drugs
zilovertamab vedotin
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03833180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833180.